Literature DB >> 33387333

Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis.

Mingqia Wang1,2, Bin Zhang3,4, Yangling Zhou1,2, Chengyu Wang1,2, Wei Zheng1,2, Weijian Liu1,2, Yanni Zhan1,2, Xiaofeng Lan1,2, Yuping Ning1,2.   

Abstract

RATIONALE: Recently, the effects of ketamine on the circadian rhythm have suggested that ketamine's rapid antidepressant effects are associated with and without sleep disturbance improvement.
OBJECTIVES: Here, we evaluated the antidepressant efficacy of repeated ketamine infusions in patients with sleep disturbances.
METHODS: This study included 127 patients with major depressive disorder or bipolar disorder who received ketamine treatments during a 12-day period. Sleep quality was assessed by the 17-item Hamilton Depression Rating Scale sleep disturbance factor (SDF) (items 4, 5 and 6). Serum brain-derived neurotrophic factor (BDNF) was measured at baseline, day 13 and day 26. This study was a post-hoc analysis.
RESULTS: Significant differences were found in the HAMD-17 score at 13 post-infusion time points compared to baseline, as well as the scores in SDF score at each of the 7 post-infusion (4 h after each infusion excluded) time points among all patients. Logistic regression and linear correlation analyses revealed that a greater reduction in the SDF after 24 h of the first ketamine infusion resulted in a better antidepressant effect in the last two follow-up visits. Moreover, BDNF levels were significantly higher in sleep responders than in non-responders.
CONCLUSIONS: In the 127 patients, six ketamine infusions induced better therapeutic effects in sleep responders than in sleep non-responders and patients without sleep disturbances. The sleep response after repeated ketamine infusions was positively associated with high serum BDNF levels. Early sleep disturbance improvement (as early as 24 h after the first ketamine injection) may predict the antidepressant effect of repeated-dose ketamine.

Entities:  

Keywords:  Antidepressant efficacy; Bipolar disorder; Brain-derived neurotrophic factor; Early prediction; HAMD-17; Ketamine; Major depressive disorder; Sleep disturbance; Sleep improvement

Year:  2021        PMID: 33387333     DOI: 10.1007/s43440-020-00203-1

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  47 in total

1.  Insomnia and inflammation: a two hit model of depression risk and prevention.

Authors:  Michael R Irwin; Dominique Piber
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

2.  Depression prevention via digital cognitive behavioral therapy for insomnia: a randomized controlled trial.

Authors:  Philip Cheng; David A Kalmbach; Gabriel Tallent; Christine Lm Joseph; Colin A Espie; Christopher L Drake
Journal:  Sleep       Date:  2019-10-09       Impact factor: 5.849

3.  Sleep complaints and depression in an aging cohort: A prospective perspective.

Authors:  R E Roberts; S J Shema; G A Kaplan; W J Strawbridge
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

4.  Potentiation of antidepressant medications by phase advance of the sleep-wake cycle.

Authors:  D A Sack; J Nurnberger; N E Rosenthal; E Ashburn; T A Wehr
Journal:  Am J Psychiatry       Date:  1985-05       Impact factor: 18.112

Review 5.  The neurobiology, investigation, and treatment of chronic insomnia.

Authors:  Dieter Riemann; Christoph Nissen; Laura Palagini; Andreas Otte; Michael L Perlis; Kai Spiegelhalder
Journal:  Lancet Neurol       Date:  2015-04-12       Impact factor: 44.182

Review 6.  Sleep, insomnia, and depression.

Authors:  Dieter Riemann; Lukas B Krone; Katharina Wulff; Christoph Nissen
Journal:  Neuropsychopharmacology       Date:  2019-05-09       Impact factor: 7.853

Review 7.  Insomnia as a health risk factor.

Authors:  Daniel J Taylor; Kenneth L Lichstein; H Heith Durrence
Journal:  Behav Sleep Med       Date:  2003       Impact factor: 2.964

8.  Phase advance of the circadian sleep-wake cycle as an antidepressant.

Authors:  T A Wehr; A Wirz-Justice; F K Goodwin; W Duncan; J C Gillin
Journal:  Science       Date:  1979-11-09       Impact factor: 47.728

9.  Functional Connectivities in the Brain That Mediate the Association Between Depressive Problems and Sleep Quality.

Authors:  Wei Cheng; Edmund T Rolls; Hongtao Ruan; Jianfeng Feng
Journal:  JAMA Psychiatry       Date:  2018-10-01       Impact factor: 21.596

Review 10.  Sleep disorders as core symptoms of depression.

Authors:  David Nutt; Sue Wilson; Louise Paterson
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more
  2 in total

Review 1.  The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.

Authors:  Giordano Novak Rossi; Jaime E C Hallak; Glen Baker; Serdar M Dursun; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-13       Impact factor: 5.760

2.  A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants.

Authors:  Okko Alitalo; Roosa Saarreharju; Ioline D Henter; Carlos A Zarate; Samuel Kohtala; Tomi Rantamäki
Journal:  Prog Neurobiol       Date:  2021-08-14       Impact factor: 10.885

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.